• Mashup Score: 3
    KRAS G12C Mutations with Dr. Tetsuya Mitsudomi | IASLC - 3 year(s) ago

    This episode of Lung Cancer Considered covers recent promising results with new targeted agents for NSCLC harboring a KRAS G12C mutation. Thoracic oncologists h …

    Source: IASLC
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of IASLC
      IASLC

      #LungCancerConsidered covers promising results with new targeted agents for #NSCLC harboring a #KRAS #G12C mutation. Results presented at #WCLC20 from #CodeBreak100 trial provide hope that new therapies will be available. https://t.co/yEoBPMSqid @StephenVLiu @t_mitsudomi

  • Mashup Score: 2
    Past Meetings & Webinars | IASLC - 3 year(s) ago

    The International Association for the Study of Lung Cancer (IASLC) is the only global network dedicated to the study and eradication of lung cancer and other thoracic malignancies.

    Source: IASLC
    Categories: Hem/Oncs, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of StephenVLiu
      StephenVLiu

      It's your last chance to access the @IASLC #WCLC20 and #TTLC21 meeting content on the virtual platform. You can still register or login to watch these on demand talks, download presentations and experience the content through April 30, 2021. #LCSM https://t.co/spKw3ajPOw

  • Mashup Score: 1
    Next Up in NSCLC: Antibody-Drug Conjugates - The ASCO Post - 3 year(s) ago

    Antibody-drug conjugates directed against HER2, HER3, and trophoblast cell-surface antigen 2 (TROP2) are showing encouraging antitumor activity in advanced non–small cell lung cancer (NSCLC), according to research presented during the virtual edition of the International Association for the Study of Lung Cancer (IASLC)…

    Source: ascopost.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of ASCOPost
      ASCOPost

      Next Up in NSCLC: Antibody-Drug Conjugates https://t.co/8GG9A53TgV #WCLC20 #LCSM #oncology #cancer

  • Mashup Score: 4
    Ipilimumab + Pembrolizumab Shows No Benefit for Patients With NSCLC - 3 year(s) ago

    The addition of ipilimumab to pembrolizumab does not improve efficacy among metastatic non-small cell lung cancer (NSCLC) patients with high levels of PD-L1 expression, according to Phase III findings presented at the International Association for the Study of Lung Cancer World Conference on Lung Cancer (Abstract PS01.09). The research was published simultaneously in the Journal of Clinical…

    Source: know.lww.com
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of OncologyTimes
      OncologyTimes

      Ipilimumab + Pembrolizumab Shows No Benefit for Patients With Non-Small Cell Lung Cancer https://t.co/cTk0UjjH7o #cancertreatment #WCLC20 #LCSM via @MichaelBoyer1 @Sydney_Uni https://t.co/6YMmCDXT2n

  • Mashup Score: 1
    Pembro +/- ipi in metastatic NSCLC: KEYNOTE-598 - 3 year(s) ago

    Pembrolizumab monotherapy has been shown to significantly prolong survival in metastatic non-small cell lung cancer (NSCLC) compared to platinum-doublet chemotherapy….

    Source: VJOncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      VIDEO: Pembro +/- ipi in metastatic #NSCLC in KEYNOTE-598 w/ @MartinReck2 of the German Center of Lung Research 👉https://t.co/3FFsONHobA👈 @VJOncology @OncoAlert @IASLC #WCLC20 #LCsm #LungCancer #TrialUpdate #ImmunoOnc #OncoAlert #Oncology #ClinOnc #MedOnc

  • Mashup Score: 0
    KEYNOTE-598: pembro + ipi in metastatic NSCLC - 3 year(s) ago

    Michael Boyer, MBBS, FRACP, PhD, Chris O’Brien Lifehouse, Camperdown, NSW, Australia, discusses the results of the Phase III KEYNOTE-598 trial…

    Source: VJOncology
    Categories: Hem/Onc News and Journals, Latest Headlines
    Tweet Tweets with this article
    • Profile photo of VJOncology
      VJOncology

      VIDEO: KEYNOTE-598: pembrolizumab plus ipilimumab in metastatic NSCLC w/ Michael Boyer of @COBLH: 👉https://t.co/9GgiKSo58E👈 @VJOncology @OncoAlert @IASLC #WCLC20 #LCSM #LungCancer #TrialUpdate #ImmunoOnc #OncoAlert #Oncology #ClinOnc #MedOnc

Load More